PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
about
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerRegulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2Emerging role of cell polarity proteins in breast cancer progression and metastasisPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerHS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapyMolecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapyMRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.PI(3,4)P2 plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cellsPatient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancersThe PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markersVimentin as an integral regulator of cell adhesion and endothelial sprouting.Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancersYiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate CancersBuparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA RepairAnti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models.An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancerRibavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potentialPrediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.Overexpression of Raf-1 in basal-like carcinoma of the breast: correlation with clinicopathology and prognosis.Targeting PTEN-defined breast cancers with a one-two punch.Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.Elevated PI3K signaling drives multiple breast cancer subtypes.ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathwaysMolecular basis of triple negative breast cancer and implications for therapy.Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor genePartial PTEN deletion is linked to poor prognosis in breast cancerHigh EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.Variants on the promoter region of PTEN affect breast cancer progression and patient survival.
P2860
Q24338724-2E0B6C97-DA7F-4FE6-836A-5AF0AB15D3BAQ24623513-5301E43D-6CF4-4841-9986-D0A1CE974C24Q26851833-05A417A1-4134-4F6D-BFFF-A160EF9429FEQ27006181-DB392DDA-8328-4386-AE38-9E3E8D7FCBA5Q28383826-17EB331B-0F15-4EC4-93E5-F77315549BB0Q28535227-44AC3CD4-B1B7-4AF1-9823-F0179AAA3773Q30881669-F24F6053-23BD-4C46-A82C-77061B964D30Q33552870-9F690284-96EB-489B-A8E1-5E3D5A77F2ADQ33738762-70B0965D-5BAF-4BCD-AC50-829B46B54206Q33739184-0C1270AD-B457-4682-9FB4-0A4965513D72Q34066386-5196BF1F-9D20-49CE-9FDB-49D876A4DE4EQ34112879-0225BA8A-AA2B-4CEF-B410-E762FE407F24Q34153121-8745925F-C4B0-46DB-9D53-51BCCB3DBEE1Q34229795-3E1F2B4B-945A-4FD1-9B0A-D7A4A492F234Q34258373-9DC252F7-DE49-4E80-958D-1FB7966A5F6BQ34395548-40055CD6-9F33-4EA0-BB60-0FC77D89419BQ34432878-0667A230-702C-4F7B-8A59-DECC7BBA7D91Q34441761-032FC1F8-087C-465A-9BAC-D1AC95BE4877Q34456552-BB1BF89A-1F7B-4043-881D-CC453A6F6FB9Q34461019-7DE99F4E-2BC7-417D-842E-67276A1EAEACQ34481443-12004F61-8867-43AE-8F66-1D9B50C3789AQ34612111-D880560E-AB87-44D5-8916-EDD1BE46FD0CQ34776985-63C0C672-88C4-4C15-AC1D-487BFBA84C27Q34917506-AED8A07A-2F7E-4E5C-96C1-21CBECC4C817Q35000243-DAC4DFEA-5D6D-4E46-B832-5B2F344A76C2Q35000248-BC195381-055F-42D5-BA2C-3B3AA1C6C1CDQ35125648-15593204-2639-462E-9007-7D486757E21BQ35165561-76AD011D-878B-44DE-913A-788219A24B95Q35312683-C1864C73-8177-4628-8E3F-C62AF0500EF0Q35492620-76F95E7B-738C-4C2A-AEE7-3299C156EDDFQ35562967-993B048D-DA05-46DF-BCF2-8774D0098049Q35584560-2AE3DDA1-E7C7-46EF-8ECC-93000F7875F0Q35640263-241C8B77-FE5B-4839-A150-D201F1B6F84AQ35646230-11808E05-204F-47FF-AA49-1E3605750376Q35684581-EFC58FE2-8F08-41C2-BB31-2AB2D4B13448Q35745395-9C84725A-47A6-4DFF-8E74-928DF41C595CQ35857671-F9A4841C-DB03-4EBE-AFA0-11EC0C502AA4Q35870069-9D79FB25-DE78-4496-B952-C2AF3ADF90E9Q35872476-1AC41A0D-FBBF-4DD7-B011-4B7B35C1FA61Q35889659-6A3E51FF-131C-4ACC-98C7-D7926FF8B87E
P2860
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
PI3K pathway activation in bre ...... and cancer-specific mortality.
@en
PI3K pathway activation in bre ...... and cancer-specific mortality.
@nl
type
label
PI3K pathway activation in bre ...... and cancer-specific mortality.
@en
PI3K pathway activation in bre ...... and cancer-specific mortality.
@nl
prefLabel
PI3K pathway activation in bre ...... and cancer-specific mortality.
@en
PI3K pathway activation in bre ...... and cancer-specific mortality.
@nl
P2093
P356
P1476
PI3K pathway activation in bre ...... and cancer-specific mortality.
@en
P2093
Catriona M McNeil
Elena López-Knowles
Elizabeth A Musgrove
Ewan K A Millar
Robert L Sutherland
Sandra A O'Toole
P304
P356
10.1002/IJC.24831
P577
2010-03-01T00:00:00Z